Delivery Order SPE2DB24D2205-SPE2DB25FEGSH
- Not listed
- The Defense Logistics Agency awarded a $42,650.28 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 7, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain lung cancers, and this award...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this delivery order represents one...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- The Defense Logistics Agency awarded a $58,164.68 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 24, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this order supports the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $10,662.57. This firm fixed-price delivery order, which is expected to be completed by October 3, 2025, represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used...
- The Defense Logistics Agency awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on September 12, 2025, with completion expected by October 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is an oncology medication used in the treatment of non-small cell lung cancer,...
- The Defense Logistics Agency awarded a $10,662.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tagrisso 80 mg tablets (30-count units) on August 15, 2025, with completion targeted for September 8, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tagrisso 80 mg tablets in a quantity of 30 units, with a contract ceiling value of $10,662.57. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is scheduled for completion by September 30, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $63,975.42. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively obtained. The order is scheduled for ultimate completion by August 4, 2025, with fulfillment taking place at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $21,325.14 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price contract with an ultimate completion date of October 9, 2025. The award represents a non-set-aside, competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGSHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,641.07 to AmerisourceBergen Drug Corp for the supply of Tagrisso 40 mg tablets (30-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy used in treating certain lung cancers, reflecting the critical pharmaceutical products procured through federal medical supply channels for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and prime vendor for the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen Drug Corp supplies an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The company's established federal procurement presence and track record of fulfilling open competition requirements position it as a critical supplier for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.6k | 8/22/25 |